Two researchers praised Novo Nordisk's obesity drug but didn't disclose payments
A Danish organization criticizes how two researchers were given a platform to talk about obesity treatment Wegovy without mentioning they had previously been paid by the drugmaker.
by mathias julius falkengaard, translated by daniel pedersen
Two Danish researchers, Tina Vilsbøll and Filip Krag Knop, have both praised Novo Nordisk’s obesity drug Wegovy, which was very recently launched in Denmark, to domestic broadcasters TV2 and DR.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Norway denies Novo Nordisk reimbursement for obesity drug
For subscribers
